These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 21432582)

  • 1. Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.
    Gerwe M; Stollhoff K; Mossakowski J; Kuehle HJ; Goertz U; Schaefer C; Bogdanow M; Heger S
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):175-86. PubMed ID: 21432582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ; Chou MC; Tzang RF; Hsu YC; Gau SS; Chen SJ; Wu YY; Huang YF; Liang HY; Cheng H
    Psychiatry Clin Neurosci; 2009 Apr; 63(2):167-75. PubMed ID: 19335386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.
    Zheng Y; Wang YF; Qin J; Wang LW; Zou LP; Jin XM; Xu T; Wang Y; Qi YL; Gong ME; Yin QY; Mai JN; Jing J; Luo XY; Ma HW; Li HB; Xie L; Li Y; Kuang GF; Yi MJ; Wang F; Zhu XH; Yao YB
    Chin Med J (Engl); 2011 Oct; 124(20):3269-74. PubMed ID: 22088519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
    Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study.
    Wilens T; Pelham W; Stein M; Conners CK; Abikoff H; Atkins M; August G; Greenhill L; McBurnett K; Palumbo D; Swanson J; Wolraich M
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):424-33. PubMed ID: 12649629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
    Fallu A; Richard C; Prinzo R; Binder C
    Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Switching from a short-acting to a long-acting methylphenidate preparation: a multicentre, open study in children with ADHD].
    Heger S; Trott GE; Meusers M; Schulz E; Rothenberger A; Rettig K; Medori R; Schreiner A; Remschmidt H;
    Z Kinder Jugendpsychiatr Psychother; 2006 Jul; 34(4):257-65. PubMed ID: 16927568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of methylphenidate on the quality of life in children with epilepsy and attention deficit hyperactivity disorder: and open-label study using an osmotic-controlled release oral delivery system.
    Yoo HK; Park S; Wang HR; Lee JS; Kim K; Paik KW; Yum MS; Ko TS
    Epileptic Disord; 2009 Dec; 11(4):301-8. PubMed ID: 20007067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, open-label trial to evaluate the quality of life in adults with ADHD treated with long-acting methylphenidate (OROS MPH): Concerta Quality of Life (CONQoL) study.
    Mattos P; Louzã MR; Palmini AL; de Oliveira IR; Rocha FL
    J Atten Disord; 2013 Jul; 17(5):444-8. PubMed ID: 22334621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS MPH Results of a 3-week open-label study.
    Remschmidt H; Hoare P; Ettrich C; Rothenberger A; Santosh P; Schmidt M; Spender Q; Tamhne R; Thompson M; Tinline C; Trott GE; Medori R
    Eur Child Adolesc Psychiatry; 2005 Sep; 14(6):297-304. PubMed ID: 16220213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
    Kim Y; Shin MS; Kim JW; Yoo HJ; Cho SC; Kim BN
    Hum Psychopharmacol; 2009 Mar; 24(2):95-102. PubMed ID: 19226534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder.
    Hammerness P; Wilens T; Mick E; Spencer T; Doyle R; McCreary M; Becker J; Biederman J
    J Pediatr; 2009 Jul; 155(1):84-9, 89.e1. PubMed ID: 19394037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
    Abikoff H; Nissley-Tsiopinis J; Gallagher R; Zambenedetti M; Seyffert M; Boorady R; McCarthy J
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):166-75. PubMed ID: 19127171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
    Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.